Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

r and lead medical negotiator for FDA interactions for AIR(R) Insulin, Lilly's inhaled insulin program.

During its first five years of development, Dr. Muchmore was the sole physician on the Lilly inhaled insulin development effort and the AIR(R) Insulin team. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase III. Dr. Muchmore's responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme's proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Prior to leading Lilly's inhaled insulin program, Dr. Muchmore served on the Evista Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. He is the recipient of numerous awards for professional achievement, including the Eli Lilly Global Brand Development Team Leadership Award in 2007.

From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, UCSD, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore also served as visiting endocrinologist at the Logan Heights Community Clinic in San Diego. He received his AB degree in Biological Sciences from Stanford University, his MD from UCSD, and initiated his internship and residency training in internal medicine at the University of Washington Affiliated Hospitals in Seattle, Washington. He finished his residency training in 1978 at the Martinez Veterans Hospital, affiliated with the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism, followed by Instructorship in Medicine, at University Hospital, Seattle in 1982.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... 2014   Synthetic Biologics, Inc. (NYSE ... biologic and drug programs targeting specific pathogens that ... its novel C. difficile development program ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ... Synthetic Biologics, Senior Vice President, ...
(Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... 16 NanoSmart™ Pharmaceuticals, Inc., a California corporation developing ... received a Notice of Allowance for a US patent ... "We have taken an approach to targeting tumors that ... CEO of the company. "While most of cancer research ...
... Announces Record Second Quarter 2010 Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia/ -- ... ... --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Aug. 16 NeoStem, Inc. (NYSE Amex: ... company with product and service revenues, global research and ... U.S. adult stem cells, China adult stem cells, and ... quarter 2010. Second Quarter Results ...
Cached Biology Technology:NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 3Nutrastar International Inc. Announces Record Second Quarter 2010 Results 4Nutrastar International Inc. Announces Record Second Quarter 2010 Results 5Nutrastar International Inc. Announces Record Second Quarter 2010 Results 6Nutrastar International Inc. Announces Record Second Quarter 2010 Results 7Nutrastar International Inc. Announces Record Second Quarter 2010 Results 8Nutrastar International Inc. Announces Record Second Quarter 2010 Results 9Nutrastar International Inc. Announces Record Second Quarter 2010 Results 10NeoStem Provides Second Quarter Update 2NeoStem Provides Second Quarter Update 3NeoStem Provides Second Quarter Update 4
(Date:8/20/2014)... In leaves, photosystem 1 (PS1) absorbs light and ... of carbon dioxide to biomass. Photovoltaic devices, mostly ... light but produce electricity. One approach for the ... replacing the semi-conductor with the isolated membrane protein ... isolates a highly stable PS1 from thermophilic cyanobacteria ...
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... students, chances of completing introductory biology courses and ... implemented a comprehensive student success program, employing various ... , Through a grant from the Texas Higher ... and Biochemistry embarked on a pilot program focusing ... and "Introductory Biology" for science majors. These two ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... The Press Room will be on the fifth floor of ... the Main Lecture Room, offering free wireless access, the book ... January 6 through Friday, January 8, 7:30 a.m.-5:00 p.m., and ... press is free. Two events are open to the ...
... glioma, the most common primary brain tumor, new findings ... cancer. A UCSF-led team of scientists has identified ... stem cells underly a type of glioma called oligodendroglioma. ... to therapy than other brain tumors such as glioblastoma ...
... the allergic reactions that asthmatics suffer towards a common ... had the mould growing in their own lungs. ... Glenfield Hospital has been published in the December 2010 ... Critical Care Medicine . The team based in ...
Cached Biology News:Joint Mathematics Meetings in New Orleans Jan. 6-9 2Joint Mathematics Meetings in New Orleans Jan. 6-9 3Joint Mathematics Meetings in New Orleans Jan. 6-9 4Joint Mathematics Meetings in New Orleans Jan. 6-9 5Joint Mathematics Meetings in New Orleans Jan. 6-9 6Joint Mathematics Meetings in New Orleans Jan. 6-9 7Cell of origin for brain tumors may predict response to therapy 2Cell of origin for brain tumors may predict response to therapy 3New asthma research breaks the mold 2
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: